LAVA THERAPEUTICS NV (LVTX)
NL0015000AG6 - Common Stock
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
LVTX stock results show that LAVA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips LAVA Therapeutics (NASDAQ:LVTX) just reported results for the fourth quarter of...
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for...
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023...
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!
LAVA stock rises on clinical trial collaboration with Merck (NASDAQ:LVTX)
LAVA Therapeutics surges as it partners with Merck for a clinical trial collaboration and supply agreement, boosting prostate cancer drug prospects.
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the...
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2...
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused...
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead...
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused...
Lava Therapeutics shelves hematology drug over competitive concerns (NASDAQ:LVTX)
Lava Therapeutics (LTRX) said that it is discontinuing development of its hematology drug candidate LAVA-051 over competitive concerns and will instead focus on its lead program.
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
• LAVA-1207 for the treatment of prostate cancer will continue as the lead program• LAVA-051 Phase 1/2a clinical trial will be discontinued• Associated...
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for a dive into the biggest pre-market stock movers for Friday as we check out the winners and losers this morning!
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.In May 2020, LAVA entered...
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on...